| Literature DB >> 35326564 |
Cosimo Rupe1, Alessia Basco1, Anna Schiavelli1, Alessandra Cassano2, Francesco Micciche'3, Jacopo Galli4, Massimo Cordaro1, Carlo Lajolo1.
Abstract
(1) Background: The general hypothesis that HNC patients show compromised oral health (OH) is generally accepted, but it is not evidence-based. The objective of this baseline report of a prospective observational study was to describe the oral health of a cohort of patients with HNC at the time of dental evaluation prior to radiotherapy (RT). (2) Materials andEntities:
Keywords: DMFt; dental caries; head and neck cancer; oral status; periodontitis
Year: 2022 PMID: 35326564 PMCID: PMC8945997 DOI: 10.3390/cancers14061411
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
General characteristics of the population and correlation with OH.
| Total Sample | Good OH | Poor OH | Significance | ||
|---|---|---|---|---|---|
| Gender | Men | 128 (65.6%) | 26 | 102 | χ2 Test— |
| Women | 67 (34.4%) | 23 | 44 | ||
| Age | Mean (range; SD) | 60.4 (22–92; 12.4) | 50.4 (22–86; 13.4) | 63.7 (40–92; 10) | Pearson’s Correlation Analysis— |
| <40 | 9 (4.6%) | 9 | 0 | ||
| 40–49 | 26 (13.4%) | 14 | 12 | ||
| 50–59 | 50 (25.6%) | 13 | 37 | ||
| 60–69 | 65 (33.3%) | 11 | 54 | ||
| 70–79 | 37 (19.0%) | 0 | 37 | ||
| >80 | 8 (4.1%) | 2 | 6 | ||
| Tumor Type | SCC | 173 (88.7%) | 44 | 129 | - |
| Other types | 22 (11.3%) | 5 | 17 | ||
| Tumor Stage | Stage I | 13 (6.7%) | 3 | 10 | - |
| Stage II | 31 (15.9%) | 12 | 19 | ||
| Stage III | 49 (25.1%) | 9 | 40 | ||
| Stage IV | 102 (52.3%) | 25 | 77 | ||
| Tumor Site | Hypopharynx | 6 (3.1%) | 2 | 4 | χ2 Test— |
| Larynx | 44 (22.6%) | 6 | 38 | ||
| Oral cavity | 41 (21%) | 9 | 32 | ||
| Oropharynx | 49 (25.1%) | 13 | 36 | ||
| Rhinopharynx | 23 (11.8%) | 13 | 10 | ||
| Salivary glands | 15 (7.7%) | 2 | 13 | ||
| Other sites | 17 (8.7%) | 4 | 13 | ||
| Smoking | Smokers | 125 (64.1%) | 22 | 103 | χ2 Test— |
| No smokers | 70 (35.9%) | 27 | 43 | ||
| Diabetes | Yes | 11 (5.6%) | 2 | 9 | - |
| No | 184 (94.4%) | 47 | 137 | ||
| Surgery a | Performed | 86 (44.1%) | 17 | 69 | - |
| Not performed | 109 (55.9%) | 32 | 77 | ||
| Chemotherapy | Scheduled | 104 (53.3%) | 30 | 74 | - |
| Not scheduled | 91 (46.7%) | 19 | 72 | ||
| Total | 195 (100%) | 49 | 146 |
a Major oncologic surgery (i.e., fibula free flap for mandible reconstruction, glossectomy). SCC: squamous cell carcinoma.
Oral health parameters of the studied population and correlation with OH. SD: standard deviation.
| Total | Good OH | Poor OH | Significance | ||
|---|---|---|---|---|---|
| Edentulism | Edentulous patients | 8 (4.1%) | 0 | 8 | - |
| Non-edentulous patients | 187 (95.9%) | 49 | 138 | ||
| 195 (100%) | |||||
| Periodontitis | Affected patients | 150 (76.9%) | 16 | 134 | χ2 Test— |
| Non-affected patients | 45 (23.1%) | 33 | 12 | ||
| 195 (100%) | |||||
| Periodontal Staging | Stage I | 21 (14%) | 9 | 12 | χ2 Test— |
| Stage II | 22 (14.7%) | 7 | 15 | ||
| Stage III | 42 (28%) | 0 | 42 | ||
| Stage IV | 65 (43.3%) | 0 | 65 | ||
| 150 (100%) | |||||
| Periodontal Grading | Grade A | 40 (26.7%) | 5 | 35 | - |
| Grade B | 66 (44%) | 10 | 56 | ||
| Grade C | 44 (29.3%) | 4 | 40 | ||
| 150 (100%) | |||||
| DMFt | Median (range) | 16 (0–32) | 8 (0–13) | 20 (0–32) | Pearson’s Correlation Analysis— |
| DMFt ≥ 13 | No | 80 (41.0%) | 49 | 31 | χ2 Test— |
| Yes | 115 (59.0%) | 0 | 115 | ||
| 195 (100%) | |||||
| Mouth Opening | Mean (range; SD) | 38.8 (12–63; 10.1) | 38.6 (12–54; 11.1) | 39.1 (12–63; 9.8) | - |
| <20 mm | 21 (10.8%) | 7 | 14 | - | |
| ≥20 mm | 174 (89.2%) | 42 | 132 | ||
| 195 (100%) | |||||
| 195 (100%) | 49 | 146 |
General and oral health characteristics of the studied population, according to the localization of the tumor.
| Larynx | Oral Cavity | Oropharynx | Rhinopharynx | Salivary Glands | Other Sites | Total Sample | Significance | ||
|---|---|---|---|---|---|---|---|---|---|
| Gender | Male | 35 (27.3%) | 23 (18%) | 38 (29.7%) | 11 (8.6%) | 9 (7%) | 12 (9.4%) | 128 (100%) | χ2 Test— |
| Female | 9 (13.4%) | 18 (26.9%) | 11 (16.4%) | 12 (17.9%) | 6 (9%) | 11 (16.4%) | 67 (100%) | ||
| Age | <40 | 0 (0%) | 2 (22.2%) | 0 (0%) | 4 (44.4%) | 1 (11.1%) | 2 (22.2%) | 9 (100%) | Pearson’s Correlation Analysis— |
| 40–49 | 6 (23.1%) | 5 (19.2%) | 6 (23.1%) | 4 (15.4%) | 1 (3.8%) | 4 (15.4%) | 26 (100%) | ||
| 50–59 | 12 (24%) | 11 (22%) | 14 (28%) | 4 (8%) | 4 (8%) | 5 (10%) | 50 (100%) | ||
| 60–69 | 15 (23.1%) | 12 (18.5%) | 21 (32.3%) | 9 (13.8%) | 2 (3%) | 6 (9.3%) | 65 (100%) | ||
| 70–79 | 11 (29.7%) | 7 (18.9%) | 8 (21.6%) | 2 (5.4%) | 4 (10.9%) | 5 (13.5%) | 37 (100%) | ||
| >80 | 0 (0%) | 4 (50%) | 0 (0%) | 0 (0%) | 3 (37.5%) | 1 (12.5%) | 8 (100%) | ||
| Tumor Type | SCC | 44 (25.4%) | 39 (22.5%) | 47 (27.1%) | 22 (12.7%) | 3 (1.7%) | 18 (10.4%) | 173 (100%) | - |
| Other types | 0 (0%) | 2 (9.1%) | 2 (9.1%) | 1 (4.5%) | 12 (54.4%) | 5 (22.7%) | 22 (100%) | ||
| Tumor Stage | Stage I | 3 (23%) | 1 (7.7%) | 4 (30.8%) | 1 (7.7%) | 2 (15.4%) | 2 (15.4%) | 13 (100%) | - |
| Stage II | 9 (29%) | 3 (9.7%) | 6 (19.4%) | 6 (19.4%) | 6 (19.4%) | 1 (3.2%) | 31 (100%) | ||
| Stage III | 9 (18.4%) | 8 (16.3%) | 16 (32.6%) | 7 (14.4%) | 3 (6.1%) | 6 (12.2%) | 49 (100%) | ||
| Stage IV | 23 (22.6%) | 29 (28.4%) | 23 (22.6%) | 9 (8.8%) | 4 (3.9%) | 14 (13.7%) | 102 (100%) | ||
| Chemotherapy | Scheduled | 15 (14.4%) | 18 (17.4%) | 38 (36.5%) | 17 (16.3%) | 4 (3.8%) | 12 (11.6%) | 104 (100%) | χ2 Test— |
| Not scheduled | 29 (31.9%) | 23 (25.4%) | 11 (12%) | 6 (6.7%) | 11 (12%) | 11 (12%) | 91 (100%) | ||
| Surgery | Performed | 19 (22.1%) | 35 (40.7%) | 6 (7%) | 3 (3.5%) | 13 (15.1%) | 10 (11.6%) | 86 (100%) | χ2 Test— |
| Not performed | 25 (23%) | 6 (5.5%) | 43 (39.4%) | 20 (18.3%) | 2 (1.9%) | 13 (11.9%) | 109 (100%) | ||
| Smoking | Yes | 38 (30.4%) | 25 (20%) | 34 (27.2%) | 10 (8%) | 6 (4.8%) | 12 (9.6%) | 125 (100%) | χ2 Test— |
| No | 6 (8.6%) | 16 (22.9%) | 15 (21.4%) | 13 (18.6%) | 9 (12.9%) | 11 (15.6%) | 70 (100%) | ||
| Edentulism | Yes | 3 (37.5%) | 2 (25%) | 1 (12.5%) | 0 (0%) | 2 (25%) | 0 (0%) | 8 (100%) | - |
| No | 41 (22%) | 39 (20.8%) | 48 (25.7%) | 23 (12.3%) | 13 (6.9%) | 23 (12.3%) | 187 (100%) | ||
| Periodontitis | Not affected | 6 (13.3%) | 10 (22.2%) | 9 (20%) | 11 (24.5%) | 3 (6.7%) | 6 (13.3%) | 45 (100%) | - |
| Stage I and II | 8 (18.7%) | 6 (13.9%) | 15 (34.9%) | 5 (11.7%) | 3 (6.9%) | 6 (13.9%) | 43 (100%) | ||
| Stage III and IV | 30 (28%) | 25 (23.4%) | 25 (23.4%) | 7 (6.5%) | 9 (8.4%) | 11 (10.3%) | 107 (100%) | ||
| DMFt | Median | 21 | 15 | 16 | 10 | 19 | 14 | 16 | - |
| DMFt ≥ 13 | No | 11 (13.8%) | 18 (22.5%) | 22 (27.5%) | 15 (18.8%) | 3 (3.7%) | 11 (13.7%) | 80 (100%) | χ2 Test— |
| Yes | 33 (28.7%) | 23 (20%) | 27 (23.5%) | 8 (7%) | 12 (10.4%) | 12 (10.4%) | 115 (100%) | ||
| Mouth Opening (mm) | <25 | 3 (14.3%) | 7 (33.3%) | 6 (28.6%) | 1 (4.8%) | 2 (9.5%) | 2 (9.5%) | 21 (100%) | - |
| ≥25 | 41 (23.6%) | 34 (19.5%) | 43 (24.7%) | 22 (12.6%) | 13 (7.5%) | 21 (12.1%) | 174 (100%) | ||
| Oral Health | Good | 6 (12.2%) | 9 (18.5%) | 13 (26.5%) | 13 (26.5%) | 2 (4.1%) | 6 (12.2%) | 49 (100%) | χ2 Test— |
| Poor | 38 (26%) | 32 (21.9%) | 36 (24.7%) | 10 (6.8%) | 13 (8.9%) | 17 (11.7%) | 146 (100%) | ||
General and oral health characteristics of the studied population, according to the habit of smoking.
| Smokers | Non-Smokers | Total Sample | Significance | ||
|---|---|---|---|---|---|
| Gender | Male | 92 (71.9%) | 36 (28.1%) | 128 (100%) | χ2 Test— |
| Female | 33 (49.2%) | 34 (50.8%) | 67 (100%) | ||
| Age | <40 | 4 (44.4%) | 5 (55.6%) | 9 (100%) | - |
| 40–49 | 16 (61.5%) | 10 (38.5%) | 26 (100%) | ||
| 50–59 | 34 (68%) | 16 (32%) | 50 (100%) | ||
| 60–69 | 43 (66.2%) | 22 (33.8%) | 65 (100%) | ||
| 70–79 | 24 (64.9%) | 13 (35.1%) | 37 (100%) | ||
| >80 | 4 (50%) | 4 (50%) | 8 (100%) | ||
| Tumor Type | SCC | 115 (66.5%) | 58 (33.5%) | 173 (100%) | |
| Other types | 10 (45.6%) | 12 (54.5%) | 22 (100%) | ||
| Tumor Site | Larynx | 38 (86.3%) | 6 (13.7%) | 44 (100%) | χ2 Test— |
| Oral cavity | 25 (61%) | 16 (39%) | 41 (100%) | ||
| Oropharynx | 34 (69.4%) | 15 (30.6%) | 49 (100%) | ||
| Rhinopharynx | 10 (43.5%) | 13 (56.5%) | 23 (100%) | ||
| Salivary glands | 6 (40%) | 9 (60%) | 15 (100%) | ||
| Other sites | 12 (52.2%) | 11 (47.8%) | 23 (100%) | ||
| Tumor Stage | Stage I | 7 (53.8%) | 6 (46.2%) | 13 (100%) | |
| Stage II | 15 (48.4%) | 16 (51.6%) | 31 (100%) | ||
| Stage III | 29 (59.2%) | 20 (40.8%) | 49 (100%) | ||
| Stage IV | 74 (72.6%) | 28 (27.4%) | 102 (100%) | ||
| Chemotherapy | Scheduled | 68 (65.4%) | 36 (34.6%) | 104 (100%) | |
| Not scheduled | 57 (62.6%) | 34 (37.4%) | 91 (100%) | ||
| Surgery | Performed | 52 (60.5%) | 34 (39.5%) | 86 (100%) | |
| Not performed | 73 (67%) | 36 (33%) | 109 (100%) | ||
| Edentulism | Yes | 4 (50%) | 4 (50%) | 8 (100%) | |
| No | 121 (64.7%) | 66 (35.3%) | 187 (100%) | ||
| Periodontitis | Not affected | 19 (42.2%) | 26 (57.8%) | 45 (100%) | χ2 Test— |
| Stage I and II | 26 (60.5%) | 17 (39.5%) | 43 (100%) | ||
| Stage III and IV | 80 (74.8%) | 27 (25.2%) | 107 (100%) | ||
| DMFt | Mean | 17.8 | 15.3 | 16.9 | |
| Median | 18 | 13 | 16 | ||
| DMFt ≥ 13 | No | 43 (53.8%) | 37 (46.2%) | 80 (100%) | χ2 Test— |
| Yes | 82 (71.3%) | 33 (28.7%) | 115 (100%) | ||
| Mouth Opening (mm) | <25 | 14 (66.6%) | 7 (33.4%) | 21 (100%) | |
| ≥25 | 111 (63.8%) | 63 (36.2%) | 174 (100%) | ||
| Oral Health | Good | 22 (44.9%) | 27 (55.1%) | 49 (100%) | χ2 Test— |
| Poor | 103 (70.5%) | 43 (29.5%) | 146 (100%) | ||
Figure 1Distribution of periodontitis according to the habit of smoking.
Figure 2Distribution of DMFt < 13 according to the habit of smoking.
Figure 3Distribution OH status according to the habit of smoking.
General and oral health characteristics of the studied population, according to the age of the subjects (decades).
| Age of the Subjects | Total Sample | Significance | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <40 | 40–49 | 50–59 | 60–69 | 70–79 | >80 | 195 (100%) | |||
| Gender | Male | 4 (3.1%) | 17 (13.3%) | 30 (23.4%) | 52 (40.6%) | 21 (16.4%) | 4 (3.1%) | 128 (100%) | |
| Female | 5 (7.5%) | 9 (13.4%) | 20 (29.9%) | 13 (19.4%) | 16 (23.8%) | 4 (6%) | 67 (100%) | ||
| Tumor Type | SCC | 6 (3.5%) | 25 (14.5%) | 44 (25.3%) | 60 (34.7%) | 32 (18.5%) | 6 (3.5%) | 173 (100%) | |
| Other types | 3 (13.7%) | 1 (4.5%) | 6 (27.3%) | 5 (22.7%) | 5 (22.7%) | 2 (9.1%) | 22 (100%) | ||
| Tumor Site | Larynx | 0 (0%) | 6 (13.7%) | 12 (27.2%) | 15 (34.1%) | 11 (25%) | 0 (0%) | 44 (100%) | χ2 Test— |
| Oral cavity | 2 (4.9%) | 5 (12.2%) | 11 (26.8%) | 12 (29.4%) | 7 (17%) | 4 (9.7%) | 41 (100%) | ||
| Oropharynx | 0 (0%) | 6 (12.2%) | 14 (28.6%) | 21 (42.9%) | 8 (16.3%) | 0 (0%) | 49 (100%) | ||
| Rhinopharynx | 4 (17.4%) | 4 (17.4%) | 4 (17.4%) | 9 (39.1%) | 2 (8.7%) | 0 (0%) | 23 (100%) | ||
| Salivary glands | 1 (6.7%) | 1 (6.6%) | 4 (26.7%) | 2 (13.3%) | 4 (26.7%) | 3 (20%) | 15 (100%) | ||
| Other sites | 2 (8.7%) | 4 (17.4%) | 5 (21.7%) | 6 (26.9%) | 5 (21.7%) | 1 (4.3%) | 23 (100%) | ||
| Tumor Stage | Stage I | 0 (0%) | 3 (23.1%) | 4 (30.8%) | 2 (15.3%) | 4 (30.8%) | 0 (0%) | 13 (100%) | |
| Stage II | 2 (6.5%) | 3 (9.7%) | 8 (25.8%) | 10 (32.3%) | 6 (19.3%) | 2 (6.4%) | 31 (100%) | ||
| Stage III | 1 (2%) | 6 (12.2%) | 14 (28.6%) | 19 (38.8%) | 8 (16.3%) | 1 (2%) | 49 (100%) | ||
| Stage IV | 6 (5.9%) | 14 (13.7%) | 24 (23.6%) | 34 (33.3%) | 19 (18.6%) | 5 (4.9%) | 102 (100%) | ||
| Chemotherapy | Scheduled | 5 (4.8%) | 17 (16.4%) | 36 (34.6%) | 35 (33.7%) | 10 (9.6%) | 1 (0.9%) | 104 (100%) | χ2 Test— |
| Not scheduled | 4 (4.4%) | 9 (9.9%) | 14 (15.4%) | 30 (32.9%) | 27 (29.7%) | 7 (7.7%) | 91 (100%) | ||
| Surgery | Performed | 2 (2.4%) | 12 (13.9%) | 24 (27.9%) | 21 (24.4%) | 22 (25.6%) | 5 (5.8%) | 86 (100%) | |
| Not performed | 7 (6.4%) | 14 (12.8%) | 26 (23.9%) | 44 (40.3%) | 15 (13.8%) | 3 (2.8%) | 109 (100%) | ||
| Smoking | Yes | 4 (3.2%) | 16 (12.8%) | 34 (27.2%) | 43 (34.4%) | 24 (19.2%) | 4 (3.2%) | 125 (100%) | |
| No | 5 (7.1%) | 10 (14.3%) | 16 (22.9%) | 22 (31.4%) | 13 (18.6%) | 4 (5.7%) | 70 (100%) | ||
| Edentulism | Yes | 0 (0%) | 0 (0%) | 0 (0%) | 2 (25%) | 5 (62.5%) | 1 (12.5%) | 8 (100%) | χ2 Test— |
| No | 9 (4.8%) | 26 (13.9%) | 50 (26.7%) | 63 (33.7%) | 32 (17.1%) | 7 (3.7%) | 187 (100%) | ||
| Periodontitis | Not affected | 7 (15.6%) | 12 (26.7%) | 15 (33.3%) | 8 (17.9%) | 2 (4.4%) | 1 (2.2%) | 45 (100%) | χ2 Test— |
| Stage I and II | 2 (4.7%) | 7 (16.4%) | 13 (30.2%) | 17 (39.5%) | 2 (4.6%) | 2 (4.6%) | 43 (100%) | ||
| Stage III and IV | 0 (0%) | 7 (6.5%) | 23 (21.5%) | 40 (37.4%) | 32 (29.9%) | 5 (4.7%) | 107 (100%) | ||
| DMFt | Median | 5 | 8 | 16 | 16 | 25 | 23 | 16 | Pearson’s Correlation Analysis— |
| DMFt ≥ 13 | No | 9 (11.3%) | 19 (23.8%) | 17 (21.2%) | 28 (35%) | 5 (6.2%) | 2 (2.5%) | 80 (100%) | χ2 Test— |
| Yes | 0 (0%) | 7 (6.1%) | 33 (28.7%) | 37 (32.2%) | 32 (27.9%) | 6 (5.2%) | 115 (100%) | ||
| Mouth Opening (mm) | <25 | 2 (9.5%) | 3 (14.3%) | 9 (42.8%) | 4 (19%) | 3 (14.3%) | 0 (0%) | 21 (100%) | - |
| ≥25 | 7 (4%) | 23 (13.3%) | 41 (23.7%) | 61 (35%) | 34 (19.5%) | 8 (4.6%) | 174 (100%) | ||
| Oral Health | Good | 9 (18.4%) | 14 (28.6%) | 13 (26.5%) | 11 (22.3%) | 0 (0%) | 2 (4.1%) | 49 (100%) | χ2 Test— |
| Poor | 0 (0%) | 12 (8.2%) | 37 (25.4%) | 54 (36.9%) | 37 (25.4%) | 6 (4.1%) | 146 (100%) | ||
Figure 4Distribution of periodontitis according to age of the patients (in decades).
Figure 5Distribution of DMFt < 13 according to age of the patients (in decades).
Figure 6Distribution of OH status according to age of the patients (in decades).